The increase of irinotecan IC50 resulting from the transfection of the GBM H4 cell line with the recombinant TDP1 clone is consistent with TDP1 activity being an important determinant of GBM sensitivity to irinotecan treatment. This evidence concerns the gene TDP1 and glioblastoma.